Patent application number | Description | Published |
20100030858 | METHOD AND SYSTEM FOR CENTRALIZED CONTACT MANAGEMENT - Disclosed is a method and system for managing contacts for a communication system by storing contact information in a centralized storage system and permitting receiving users to access the centralized contact information storage system using a token passed with communications from a sending user. The communications system may be a trusted network with trusted sending and receiving members. Each communications system member provides contact information the member may wish to make available to other parties. The member may also create a policy defining which contact information may be made available to different classes of users. A member of the communications system generates a message to send to a receiving user. A token that identifies the sending user to the communications system is embedded into the message to be sent to the receiving user. The receiving user, after identifying the message as a message containing a token, may request contact information for the sending user from the communications system using the token identifying the sending user to the communication system. The communication system delivers a subset of the sending user's contact information to the receiving user based on the sending user's contact information and policy definitions stored in the centralized contact information storage system of the communication systems. The system and method are especially adaptable to e-mail communications, but other forms of electronic communications may also be included in an embodiment, either solely or in combination. | 02-04-2010 |
20110197275 | STOPPING AND REMEDIATING OUTBOUND MESSAGING ABUSE - Systems and methods are provided for allowing subscriber message sending profiles to be maintained and used in conjunction with behavior-based anomaly detection techniques and traditional content-based spam signature filtering to enable application of appropriate message disposition policies to outbound subscriber message traffic. According to one embodiment, subscriber profiles are constructed for multiple subscriber accounts associated with a service provider based on outbound message flow originated from the subscriber accounts. Then, possible subscriber account misuse may be discovered by performing behavior-based anomaly detection, including a comparison of a subscriber profile associated with the subscriber account with recent subscriber account usage information, to identify one or more behavioral anomalies in outbound message flow originated from a subscriber account, the behavior-based anomaly detection. | 08-11-2011 |
20130041955 | Subscriber reputation filtering method for analyzing subscriber activity and detecting account misuse - Systems and methods are provided for allowing subscriber message sending profiles to be maintained and used in conjunction with behavior-based anomaly detection techniques and traditional content-based spam signature filtering to enable application of appropriate message disposition policies to outbound subscriber message traffic. According to one embodiment, subscriber profiles are constructed for multiple subscriber accounts associated with a service provider based on outbound message flow originated from the subscriber accounts. Then, possible subscriber account misuse may be discovered by performing behavior-based anomaly detection, including a comparison of a subscriber profile associated with the subscriber account with recent subscriber account usage information, to identify one or more behavioral anomalies in outbound message flow originated from a subscriber account, the behavior-based anomaly detection. | 02-14-2013 |
20130117397 | STOPPING AND REMEDIATING OUTBOUND MESSAGING ABUSE - Systems and methods are provided for allowing subscriber message sending profiles to be maintained and used in conjunction with behavior-based anomaly detection techniques and traditional content-based spam signature filtering to enable application of appropriate message disposition policies to outbound subscriber message traffic. According to one embodiment, subscriber profiles are constructed for multiple subscriber accounts associated with a service provider based on outbound message flow originated from the subscriber accounts. Then, possible subscriber account misuse may be discovered by performing behavior-based anomaly detection, including a comparison of a subscriber profile associated with the subscriber account with recent subscriber account usage information, to identify one or more behavioral anomalies in outbound message flow originated from a subscriber account, the behavior-based anomaly detection. | 05-09-2013 |
20130326622 | Trusted Communication Network - A system includes a processing node configured to send authorized inbound messages to registered enterprise networks. An authorized message is a message that includes trusted source indicia. Trusted source indicia indicates that the message was sent by one or more of the processing node or an authenticated message transfer node associated with one of the registered enterprise networks. The system may further include an administration node configured to maintain registration of a plurality of message transfer nodes associated with the enterprise networks. A method includes receiving outbound messages from an authenticated message transfer node of an enterprise network, screening the messages for threats to determine whether to send the messages to associated recipients, applying a first message identifier to each message, wherein the first message identifier can be used to track the message and, for each message, sending the message to the associated recipient if no threats are detected in the message. | 12-05-2013 |
Patent application number | Description | Published |
20100034876 | CONTROLLED RELEASE OXYCODONE COMPOSITIONS - A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed. | 02-11-2010 |
20100092570 | CONTROLLED RELEASE OXYCODONE COMPOSITIONS - A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed. | 04-15-2010 |
20130011543 | CONTROLLED RELEASE OXYCODONE COMPOSITIONS - A method for preparing a solid oral dosage form comprising up to about 160 mg of oxycodone or a salt thereof to control pain in substantially all patients is disclosed. The method comprises forming spheroids comprising a spheronising agent and oxycodone or a salt thereof, and coating the spheroids with a controlled-release film coat. Repeated “q12h” (i.e., every 12 hour) administration of the dosage form through steady-state conditions results in a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after administration. | 01-10-2013 |
20130012533 | CONTROLLED RELEASE OXYCODONE COMPOSITIONS - A method for preparing a solid oral dosage form comprising up to about 160 mg of oxycodone or a salt thereof to control pain in substantially all patients is disclosed. The method comprises wet granulating at least one hydrophilic or hydrophobic polymer, preferably a hydroxyalkyl cellulose or an alkyl cellulose, with oxycodone or a salt thereof to form a controlled-release matrix. Repeated “q12h” (i.e., every 12 hour) administration of the dosage form through steady-state conditions results in a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after administration. | 01-10-2013 |